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Abstract
The	objective	of	this	scoping	review	is	to	summarize	the	current	use	of	pharmacoki-
netics	 for	 tailoring	 prophylaxis	 in	 hemophilia	 patients	 switching	 between	 clotting	
factor	products.	Patients	with	hemophilia	may	 require	switching	of	clotting	 factor	
concentrates	due	to	a	variety	of	factors,	but	there	have	been	perceived	risks	associ-
ated	with	switching,	such	as	inhibitor	development	or	suboptimal	protection	due	to	
inadequate	dosing	while	titrating	treatment.	Studies	that	look	at	patients	switching	
from	one	 clotting	 factor	 concentrate	 to	 another	 are	 categorized	 in	 terms	 of	 their	
primary	and/or	secondary	objectives,	notably	biosimilarity	and	comparative	pharma-
cokinetic	studies	and	inhibitor	development	studies.	Research	on	how	best	to	switch	
concentrates	with	respect	to	dosing	regimen	are	 lacking,	and	currently	a	trial-and-
error	approach	is	used	for	dosing	the	new	factor	concentrate.	In	the	future,	studies	
looking	at	 the	predictability	of	pharmacokinetics	 (PK)	of	a	new	factor	concentrate	
based	on	individual	PK	knowledge	of	the	original	factor	concentrate	may	offer	clinical	
benefit	by	providing	a	safer	switching	approach	and	protocol.
K E Y W O R D S
drug	substitution,	factor	IX,	factor	VIII,	hemophilia	A,	hemophilia	B
Essentials
•	 We	assessed	use	of	pharmacokinetics	(PK)	to	tailor	hemophilia	prophylaxis	when	switching	factor	products.
•	 Identified	studies	primarily	assessed	biosimilarity	and	none	used	PK	to	inform	switching.
•	 Switching	is	common	based	on	a	review	of	the	WAPPS	database	for	both	factor	VIII	and	IX.
•	 Evidence-based	switching	methods	(eg,	population	PK)	may	improve	dosing	during	switching.
1  | INTRODUCTION
The	mainstay	treatment	of	hemophilia	involves	administration	of	fac-
tor	concentrates.	In	the	past,	factors	VIII	(FVIII)	and	IX	(FIX)	infusions	
were	given	during	or	soon	after	an	acute	bleed.	This	“on-demand”	
treatment	decreased	the	number	of	patients	with	joint	deformities	
but	 also	 significantly	 lowered	 their	 morbidity	 and	 mortality,	 ulti-
mately	increasing	their	quality	of	life.1	This	practice	was	soon	to	be	
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found	 suboptimal	 and	a	 study	by	Aledort	 et	 al	 demonstrated	 that	
severe	hemophilia	patients	without	inhibitors	undergoing	an	on-de-
mand	treatment	regimen	still	experienced	reduced	orthopedic	out-
comes	and	increased	deteriorated	joints	compared	to	those	treated	
prophylactically.1,2	Prophylactic	FVIII	or	FIX	infusion	has	now	been	
accepted	as	the	standard	for	treating	hemophilia	patients	well	be-
fore	joint	damage	is	apparent.2‒6
Prophylaxis	 was	 conceived	 as	 repeatedly	 dosing	 the	 patient	
so	as	to	obtain	a	measurable	factor	activity	at	all	times.	The	chal-
lenge	is	that	appropriate	dosing	regimens	vary	by	patient	and	fac-
tor	concentrate	and	should	be	 individualized	 from	a	 therapeutic	
and	economic	standpoint.6‒8	A	“trial-and-error”	approach	is	usu-
ally	 adopted,	which	 involves	 using	 a	 typical	 prophylactic	 dosing	
regimen	of	20	to	50	IU/kg,	a	dose	that	should	provide	the	average	
patient	 with	 hemophilia	 with	 enough	 clotting	 factor	 to	 achieve	
the	goal	of	a	trough	activity	≥0.01	IU/mL	at	48	hours.	However,	
this	trial-and-error	approach	fails	to	account	for	 individual	phar-
macokinetic	 (PK)	 variability	 and,	 as	 per	 Iorio	 et	 al,9 may lead to 
suboptimal	results.
The	trial-and-error	approach	is	used	again	when	switching	be-
tween	 factor	 concentrates.	Common	practice	 in	 this	 scenario	 is	
that	either	the	dose	is	initially	kept	the	same	as	before	the	switch	
and	frequency	is	adjusted	proportionally	to	the	relative	expected	
change	 in	terminal	half-life,	or	the	dose	and	frequency	tested	 in	
the	pivotal	studies	are	used	in	a	first	instance.	Current	guidelines	
suggest	 initiating	 extended	half-life	 (EHL)	 products	 at	 the	 same	
dose	as	standard	half-life	concentrates	but	reducing	the	infusion	
frequency	from	3	to	2	times	weekly,	and	subsequently	adjusting	
the	 dose	 based	 on	 a	 population	 pharmacokinetic	 (PopPK)	 ap-
proach.10,11	 When	 a	 person	 with	 hemophilia	 switches	 between	
factor	concentrates,	the	person	is	switching	from	a	product	with	
known	PK,	or	at	least	with	known	outcomes	(eg,	dose	required	to	
reduce	bleeding	events),	to	one	with	unknown	PK.	Dosing	a	factor	
concentrate	with	unknown	PK	introduces	the	risk	of	underdosing	
or	resource	wastage,	leading	to	increased	risk	of	bleeds	or	unnec-
essary	use	of	factor	concentrate,	respectively.
The	decision	to	switch	between	factor	concentrates	depends	on	
a	variety	of	factors,	and	shared	decision	making	while	assessing	the	
product's	safety,	efficacy,	cost,	and	convenience	is	essential	before	
introducing	a	new	product.	The	availability	of	newer	and	safer	FVIII	
concentrates	 has	 resulted	 in	 switching	 between	 different	 plasma-
derived	or	recombinant	FVIII	concentrates	throughout	the	course	of	
hemophilia	treatment.12	Newer	FVIII	products	report	to	have	better	
PK	in	terms	of	longer	half-life	and	thus	may	provide	the	advantage	
of	fewer	infusions.12	Other	reasons	for	switching	FVIII	products	may	
include	 cost	 savings,	 via	 a	 tender-based	national	 plan	 coverage	or	
otherwise,	 side	 effects,	 drug	 shortages,	 or	 hypersensitivity	 to	 the	
formulation.12
The	 optimal	 approach	 to	 dose	 selection	 when	 switching	 be-
tween	 factor	 concentrates	 remains	 unknown.	 To	 answer	 the	
question	 of	 what	 is	 known	 about	 the	 current	 use	 of	 PK	 for	 tai-
loring	 prophylaxis	 in	 people	 with	 hemophilia	 switching	 between	
factor	concentrates,	we	conducted	(1)	a	scoping	literature	review,	
searching	 for	 empirical	 evidence	 regarding	 optimal	 switching	
practice;	 and	 (2)	 a	 review	 of	 the	 Web-Accessible	 Population	
Pharmacokinetics	 Service–Hemophilia	 (WAPPS-Hemo)	 database	
available	 to	 explore	 the	 practice	 of	 switching	 as	 recorded	 in	 the	
real	world.	WAPPS-Hemo	is	a	globally	accessible	online	tool	allow-
ing	hemophilia	treaters	to	estimate	individual	PK	using	a	population	
PK	approach	based	on	a	limited	set	of	2	to	3	plasma	factor	activ-
ity	measurements	and	patient	covariates	(eg,	age,	weight,	height).	
Patient	covariates	and	PK	profiles	gathered	by	WAPPS-Hemo	are	
deidentified	and	stored	in	a	database.	This	database	is	available	for	
research	purposes	to	the	members	of	the	WAPPS-Hemo	research	
network.13	 The	WAPPS-Hemo	 database	 provides	 information	 on	
current	 practices	 regarding	 product	 switching,	 as	 patients	 who	
have	had	>1	infusion	recorded	and	have	used	>1	factor	concentrate	
can	be	tracked	within	the	system.
2  | METHODS
2.1 | Scoping review
The	scoping	review	process	followed	these	steps:	(1)	identify	possi-
ble	eligible	studies;	(2)	select	relevant	studies;	(3)	chart	the	data;	and	
(4)	collate,	summarize,	and	report	the	results,	as	proposed	by	Arksey	
and	 O'Malley.14	 Following	 the	 PCC	 mnemonic,15	 studies	 included	
hemophilia	A	or	B	patients	 (Population)	 switching	between	differ-
ent	 factor	concentrates	and	 including	appropriate	PK	assessments	
(Concept)	and	without	any	limitation	as	to	reasons	for	switching,	so-
cioeconomic	setting,	and	underlying	health	care	system	characteris-
tics	(Context).	Relevant	studies	were	prospective	in	nature.	A	search	
strategy	 was	 developed	 using	 medical	 subject	 headings	 (MeSH).	
The	 literature	 search	 was	 independently	 performed	 in	 PUBMED	
(MEDLINE)	in	September	2018	by	both	JKY	and	ANE.	Search	terms	
included:
•	 (“Hemophilia	 A”[MeSH]	 OR	 “Hemophilia	 B”[MeSH]	 OR	 “Factor	
IX”[MeSH]	OR	“Factor	VIII”[MeSH])	AND	switch*
•	 (“Hemophilia	A”[MeSH]	OR	“Hemophilia	B”[MeSH])	AND	“Cross-
Over	Studies”[MeSH]
•	 (“Hemophilia	 A”[MeSH]	 OR	 “Hemophilia	 B”[MeSH])	 AND	
“Pharmacokinetics”
•	 (“Hemophilia	 A”[MeSH]	 OR	 “Hemophilia	 B”[MeSH])	 AND	
“Bioequivalence”
2.2 | WAPPS data review
For	this	review,	all	patients	within	the	WAPPS-Hemo	database	were	
eligible	for	 inclusion	unless	they	had	only	1	 infusion	or	had	only	1	
type	of	factor	concentrate	recorded	on	multiple	occasions	(Figure	1).	
The	WAPPS	user	agreement	allows	reuse	of	the	data	for	modeling	
and	 other	 research	 purposes,	 as	 described	 in	 the	 WAPPS	 study	
protocols,	 approved	 by	 the	 ethics	 boards	 at	McMaster	University	
and	 the	 University	 of	 Waterloo	 and	 registered	 in	 clinicaltrial.gov	
(NCT02061072,	NCT03533504).
     |  3YU et al.
3  | RESULTS
3.1 | Study selection
There	were	no	research	articles	that	specifically	addressed	the	optimal	
approach	to	switching	between	factor	concentrates.	However,	there	
were	39	peer-reviewed	scientific	articles	that	fell	within	our	inclusion	
criteria	(Figure	2).	Reviewer	1	identified	39	and	reviewer	2	identified	
38	that	were	identical	to	those	selected	by	reviewer	1.	Upon	discus-
sion	of	the	missing	article,	the	reviewers	decided	to	include	it	as	it	met	
the	inclusion	criteria.	The	39	articles	were	the	only	studies	that	could	
provide	treaters	with	methods	for	evidence-based	switching	using	PK	
and	were	thus	sorted	based	on	their	primary	objective	and	appraised.	
Studies	 included	bioequivalence	or	comparative	PK	studies,	 as	well	
as	inhibitor	development	studies	during	switching.	All	39	studies	are	
outlined	in	Table	1	(FVIII)	and	Table	2	(FIX).
3.2 | Biosimilarity/bioequivalence or comparative 
PK studies
Strictly	 speaking,	 the	 term	 bioequivalence	 should	 not	 be	 used	 for	
drugs	 produced	 by	 biotechnology;	 the	 term	 biosimilarity	 is	 more	
appropriate.16	However,	bioequivalence	was	 the	 terminology	used	
in	many	of	 the	 studies	 as	many	were	published	prior	 to	 the	2014	
European	Medicines	Agency's	guidance.16	 Irrespective	of	the	term	
used,	studies	assessing	biosimilarity/bioequivalence	did	not	usually	
enhance	a	switching	protocol	as	a	primary	objective;	however,	their	
standardized	dosing	protocol	 allowed	 for	 comparison	of	 individual	
PK	profiles	 between	 the	 2	 brands	 under	 study.	 Thus,	 this	 section	
focuses	on	biosimilarity	and	comparative	PK	studies	as	both	types	
compared	population	PK.
There	were	a	 limited	number	of	studies	that	were	biosimilarity	
or	 comparative	 PK	 studies	 (n	 =	 34)	 (Tables	 1	 and	 2).	 Biosimilarity	
refers	to	a	lack	of	statistically	significant	differences	in	drug	expo-
sure	between	2	drug	products.	In	multiple	crossover	studies,	biosim-
ilarity	was	assessed	by	using	a	PK	analysis	to	derive	the	maximum	
plasma	factor	activity	 (Cmax)	 following	 infusion	and	the	area	under	
the	plasma	concentration	vs.	time	curve	(AUC).17‒19	To	establish	bio-
similarity,	the	ratio	of	the	logarithmic	geometric	mean	values	of	Cmax 
and	AUC	must	fall	within	the	 interval	of	80%	to	125%	based	on	a	
90%	confidence	interval.17,18
All	of	the	studies	looking	at	comparing	PK	between	2	brands	
used	PK	end	points,	as	suggested	by	the	International	Society	of	
Thrombosis	 and	 Haemostasis	 and	 American	 and	 European	 reg-
ulatory	 bodies.12‒14	 The	 test	 dose	 before	 and	 after	 the	 switch	
was	almost	 always	 identical,	 usually	with	a	weight-based	dosing	
of	50	IU/kg	of	the	factor	concentrates.	Using	the	same	dose	for	
different	concentrates	 is	a	 requisite	 for	biosimilarity	 studies.	All	
trials	studied	included	a	washout	period	of	between	2	and	7	days	
before	 starting	 the	 trial	 and	 between	 different	 factor	 concen-
trates	(Tables	1	and	2).
Biosimilarity/bioequivalence	 testing	 employs	 various	 types	
of	 statistics	 that	are	dependent	upon	 the	 trial	design.	Most	 trial	
designs	 for	 biosimilarity	 testing	 of	 clotting	 factors	 employed	 a	
F I G U R E  1  Study	flow	diagram	of	
WAPPS	data WAPPS Database
(n = 2785 subjects, 5152 infusions)
Subjects with >1 infusion
(n = 943 subjects, 3310 infusions)
Subjects with >1 infusion who
switched between factor concentrates
(n = 449 subjects, 1096 infusions)
1 subject associated with only 1 infusion
removed
(n = 1842 subjects, 1842 infusions)
Subjects who did not switch between factor
concentrates removed
(n = 494 subjectes, 2214 infusions)
591 switches between FVIII concentrates
(n = 394 subjectes, 985 infusions)
56 switches between FIX concentrates
(n = 55 subjectes, 111 infusions)
F I G U R E  2  Study	flow	diagram	of	
PUBMED	search
Records identified through database
searching (n = 788)
Records identified after duplicates
removed (n = 722)
Records excluded bacause of duplicates (n = 66)
Records identified after title screening
(n = 174)
Records excluded because of title screening (n = 548)
Studies excluded through abstract screening (n = 135)
Not crossover study (n = 119)
No PK evaluation (n = 6)
Not same patient on two products (n = 4)
Retrospective study (n = 4)
Not hemophilia A or B (n = 1)
Not using factor VIII or IX (n = 1)
Studies included from PUBMED
(n = 39)
•
•
•
•
•
•
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TA B L E  1  Summary	of	studies	of	hemophilia	patients	switching	between	factor	VIII	concentrates
Author Products
Dose  
(IU/kg)
No. of 
subjects 
screened 
for PK
Age range 
(mean) 
[median]
Minimum 
washout 
period (d) Primary objective
Biosimilarity	or	comparative	PK	studies
Di	Paola17 (1)	Advate 
(2)	ReFacto
50	±	5 21 19-72 
(35.8) 
[30]
3 Compare	PK	of	ReFacto	and	Advate	
to	establish	bioequivalence
Dmoszynska31 (1)	Prior	FVIII	
product 
(2)	Optivate
50 15 12-65 3 Investigate	the	PK	of	Optivate	
against	other	FVIII	products
Fijnvandraat32 (1)	rFVIII	SQ 
(2)	Octonativ	M
50 12 17-64 
(34)
4 Compare	PK	of	rFVIII	SQ	and	
Octonativ	M
Kessler18 (1)	ReFacto	(2	formu-
lations) 
(2)	Hemofil	M
50 19 18-44 
(26.3)
5 Compare	PK	of	the	2	formulations	of	
ReFacto	with	Hemofil	M	to	establish	
bioequivalence
Klamroth23 (1)	Advate 
(2)	rFVIII	single-chain
50 27 19-60 
(35.4)
4 Compare	PK	parameters	of	rFVIII	
single-chain	with	full-length	rFVIII
Martinowitz22 (1)	Advate 
(2)	N8
50 25 13-54 
(24)
4 Compare	PK	profiles	of	N8	and	
Advate	to	establish	bioequivalence
Morfini33 (1)	pdFVIII 
(2)	rFVIII
25-56 
25-45
17 15-51 
(27.7) 
[24.9]
7 Compare	PK	profiles	of	2	different	
classes	of	FVIII	concentrates
Morfini34 (1)	Recombinate 
(2)	Hemofil	M
50 47 6-62 
(26.4)
7 Compare	PK	profiles	of	Recombinate	
and	Hemofil	M
Morfini35 (1)	Hemofil	M 
(2)	Monoclate	HT 
(3)	Monoclate	P
25 10 - 7 Compare	in	vivo	behavior	among	the	
3	products
Recht36 (1)	Advate 
(2)	Xyntha
50 24 12-60 
[24]
3 Demonstrate	PK	equivalence	of	
Advate
Shah19 (1)	Advate 
(2)	Kovaltry
50 18 19-64 
(37.3) 
[36]
3 Compare	PK	profile	of	Advate	and	
Kovaltry
Shirahata37 (1)	BAY14-2222 
(2)	Kogenate
50 5 15-43 
(32) 
[35]
5 Compare	PK	profile	of	BAY14-2222	
and	Kogenate
Biosimilarity	or	comparative	PK	and	inhibitor	development	studies
Abshire38 (1)	Kogenate 
(2)	rFVIII-FS
50 35 - 4 Compare	PK	and	safety	of	Kogenate	
and	rFVIII-FS
Coyle39 (1)	rFVIII-FS 
(2)	BAY	94-9027
25/50 
25/60
14 21-58 
(36.1)
3 Assess	PK	and	safety	of	BAY	94-9027
Kulkarni40 (1)	Prior	FVIII	
product 
(2)	Turoctocog	alfa
- 
25-60
69 1-11 
(6.1)
3 Investigate	safety,	efficacy,	and	PK	
properties	of	turoctocog	alfa
Mahlangu29 (1)	Advate 
(2)	rFVIIIFc
50 30 12-65 
[29]
- Evaluate	safety,	efficacy,	and	PK	of	
rFVIIIFc
Meunier41 (1)	Prior	FVIII	
product 
(2)	N8-GP
- 
60
24 0-11 
(6.0)
- Assess	safety,	efficacy,	and	PK	of	
N8-GP
Mullins42 (1)	Advate 
(2)	BAX855
60	±	5 31 1-11 
(6) 
[6]
- Determine	immunogenicity,	PK,	
efficacy,	safety,	and	quality	of	life	
using	BAX855
(Continues)
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2	×	2	×	2	crossover	design.	All	biosimilarity	and	comparative	PK	
studies	 observed	 average	 biosimilarity	 or	 average	 mean	 PK	 pa-
rameter	 differences	 and	 did	 not	 examine	 individual	 differences.	
Average	biosimilarity	assesses	the	PK	between-subject	variability	
(BSV)	 but	 does	 not	 directly	 assess	 the	within-subject	 variability	
(WSV)	over	time.	This	may	be	reasonable	given	the	a	priori	knowl-
edge	that	clotting	factor	concentrates	demonstrate	a	high	PK	BSV	
and	 low	WSV	within	 1	 brand,6	 and	 therefore	 the	 assessment	 of	
individual	biosimilarity	may	not	be	necessary.	 Individual	biosimi-
larity	assesses	for	both	the	mean	and	variability	of	PK	metrics	and	
also	 the	 ratio	 of	 the	 2	 drug	 products	 on	 an	 individual	 basis	 and	
is	 recognized	when	both	 the	 average	biosimilarity	 is	 established	
and	 the	 subject-by-formulation	 effect	 is	 insignificant.20	 Average	
biosimilarity	is	important	to	assess	mean	PK	differences	in	a	pop-
ulation,	but	individual	biosimilarity	is	highly	impactful	if	the	goal	is	
to	give	prescribers	confidence	that	biosimilarity	will	occur	when	a	
patient	on	one	of	the	drug	products	is	switched	to	the	other.
In	order	for	a	drug	to	be	therapeutically	equivalent	to	another	
product,	 it	 requires	 the	 same	 active	 pharmaceutical	 ingredient	
(API),	 dosage	 form,	 strength,	 route	 of	 administration,	 and	 estab-
lished	bioequivalence.21	Because	clotting	factors	are	not	identical,	
as	they	are	biologics,	the	PK	BSV	and	WSV	of	the	2	brands	may	not	
hold;	this	is	not	the	case	with	small	molecules,	where	the	API	sys-
temic	disposition	is	exactly	the	same	between	2	drug	products.	As	a	
result,	the	individual	concentration-time	profile	of	1	factor	concen-
trate	can	be	different	as	compared	to	another	factor	concentrate	of	
the	same	dose	and	 frequency.	 If	 individual	biosimilarity	 for	2	 fac-
tor	concentrates	is	established,	they	can	be	used	interchangeably,	
and	the	PK	of	one	factor	concentrate	is	therefore	predictive	of	the	
other.	However,	no	study	confirming	 individual	patient	biosimilar-
ity	has	been	completed	because	it	is	difficult	to	achieve.	In	a	study	
by	Di	Paola	et	al,17	patients	who	switched	from	Advate	to	ReFacto	
had	 very	 different	 individual	 PK	 parameters	 even	 though	 the	 av-
erage	PK	parameters	were	similar.	Similar	 findings	were	observed	
with	Martinowitz	et	al22	and	Klamroth	et	al	 (Figure	3).23 The con-
clusion	that	2	factor	concentrates	are	bioequivalent	does	not	mean	
that	individuals	will	achieve	the	same	concentration-time	profile	if	
the	same	dose	is	given.	Likewise,	similar	average	half-life	between	
2	 factor	concentrates	does	not	mean	that	 the	half-life	between	2	
factor	concentrates	in	any	given	individual	will	be	similar;	some	in-
dividuals	in	Figure	3	had	drastic	differences	in	their	PK	across	factor	
concentrates.
Author Products
Dose  
(IU/kg)
No. of 
subjects 
screened 
for PK
Age range 
(mean) 
[median]
Minimum 
washout 
period (d) Primary objective
Powell43 (1)	Kogenate 
(2)	Kogenate	with	
pegylated	liposome	
carrier	(13	or	22	mg/
kg)
35 26 12-60 2 Investigate	the	safety,	tolerability,	
bioavailability,	pharmacokinetics,	
and	pharmacodynamics	of	Kogenate	
with	pegylated	liposome	barrier	
compared	with	standard	Kogenate
Schwartz44 (1)	Koate-HS 
(2)	Recombinant	
FVIII
50 
20-40
17 - 7 Compare	PK	of	plasma-derived	and	
recombinant	FVIII,	assess	efficacy	
of	recombinant	FVIII	for	home	
therapy,	and	assess	efficacy	for	
major	surgical	procedures	and	
hemorrhage
Skotnicki45 (1)	Vocento 
(2)	Biostate-RP
50 17 18-57 
(36.5) 
[37]
4 Evaluate	efficacy,	safety,	and	PK	of	
Voncento
Tiede46 (1)	Prior	FVIII	
product 
(2)	N8-GP
- 
25/50/75
26 20-60 
[36.5]
4 Evaluate	safety	and	PK	of	N8-GP	
in	comparison	with	previous	FVIII	
products
Young30 (1)	Prior	FVIII	
product 
(2)	rFVIIIFc
50 60 1-11 
[5]
3 Evaluate	safety,	efficacy,	and	PK	of	
rFVIIIFc
Inhibitor	development	studies
Hsu47 (1)	Kogenate 
(2)	Koate-HS
50 
-
12 23-53 
(37.8)
7 Evaluate	safety	and	efficacy	of	
Kogenate
Powell48 (1)	Advate 
(2)	rFVIIIFc
25/65 
25/65
19 23-61 
(34.6)
3 Evaluate	safety	and	treatment-emer-
gent	adverse	events,	development	
of	antibodies,	and	laboratory	
monitoring
-,	not	specified;	FVIII,	factor	VIII;	pdFVIII,	plasma-derived	factor	VIII;	PK,	pharmacokinetics;	rFVIII,	recombinant	factor	VIII;	SQ,	subcutaneous.
TA B L E  1   (Continued)
6  |     YU et al.
No	study	involving	switching	between	factor	concentrates	where	PK	
was	assessed	used	this	information	to	predict	a	proper	dosing	regimen.
3.3 | Inhibitor development studies
The	second	type	of	study	included	patients	serially	taking	at	least	2	clot-
ting	factor	concentrates	and	had	the	objective	of	examining	 inhibitor	
development.	Inhibitors	are	antibodies	that	neutralize	clotting	factors.	
These	inhibitors	are	generally	measured	using	the	Nijmegen	modifica-
tion	of	the	Bethesda	assay.24,25	Once	inhibitors	develop	in	a	patient	with	
hemophilia,	it	becomes	much	more	difficult	to	treat	them,	resulting	in	
an	increase	in	morbidity	and	mortality	in	the	affected	population.24,26
Eighteen	 articles	were	 identified	 in	which	 their	 primary	 out-
come	 was	 focusing	 on	 inhibitor	 development	 after	 switching	
TA B L E  2  Summary	of	studies	of	hemophilia	patients	switching	between	factor	IX	concentrates
Author Products Dose (IU/kg)
No. of 
subjects 
screened 
for PK
Age range 
(mean) 
[median]
Minimum 
washout 
period (d) Primary objective
Biosimilarity	or	comparative	PK	studies
Alamelu49 (1)	Alphanine 
(2)	Benefix
50 9 15-73 
(41.2) 
[42]
7 Compare	PK	and	pharmacodynamics	
properties	of	rFIX	and	pdFIX
Aznar50 (1)	Immunine/
Octanine 
(2)	FIX	Grifols
65-75 25 12-38 
(23.1)
7 Compare	pharmacokinetic	profile	of	
FIX	Grifols	to	available	Immunine	
or Octanine
Ewenstein51 (1)	Benefix 
(2)	Mononine
50 43 7-75 
[18.5]
7 Assess	PK	properties	of	the	2	prod-
ucts	and	address	how	variables	
affect	in	vivo	recovery	and	half-life
Goudemand52 (1)	FIX-SD-15 
(2)	FIX-SD
60 11 - 10 Compare	PK	and	coagulation	activa-
tion	markers	of	FIX-SD-15	and	
FIX-SD
Liebman53 (1)	Alphanine 
(2)	Mononine
40 12 - 7 Evaluate	kinetics	of	FIX	activity	and	
protein
Lissitchkov54 (1)	Benefix 
(2)	Alphanine
65-75 22 15-45 
(27)
7 Compare	PK	between	Benefix	and	
Alphanine
Martinowitz55 (1)	Benefix 
(2)	IB1001
75	±	5 32 15-64 5 Compare	PK	of	IB1001	with	those	
of	Benefix	and	assess	consistency	
of	PK	parameters
Thomas56 (1)	Conventional	FIX 
(2)	High-purity	FIX
75 19 - 7 Compare	PK	of	high-purity	FIX	to	
conventional	FIX
Windyga57 (1)	Benefix 
(2)	BAX326
75	±	5 86 12-65 5 Characterize	PK	profile	of	BAX326	
and	determine	PK	equivalence	with	
Benefix
Biosimilarity	or	comparative	PK	and	inhibitor	development	studies
Collins58 (1)	Benefix 
(2)	IB1001
75	±	5 32 14.8-64.5 
(32.7) 
[29.9]
5 Establish	PK	noninferiority	of	
IB1001	to	Benefix,	safety,	and	
efficacy
Kenet59 (1)	Prior	FIX	product 
(2)	rFIX-FP
50 27 1-11 
(5.9)
- Evaluate	PK,	efficacy,	and	safety	of	
rFIX-FP
Inhibitor	development	studies
Negrier60 (1)	Prior	FIX	product 
(2)	N9-GP
- 
25/50/100
20 21-55 
[30]
7 Determine	safety	by	evaluating	
adverse	events,	antibody	formation	
against	FIX	and	N9-GP,	physical	
examination,	and	clinical	laboratory	
assessments
Powell61 (1)	Benefix 
(2)	rFIXFc
50 22 - 5 Determine	annualized	bleeding	rate	
and	development	of	inhibitors
Solano	
Trujillo62
(1)	Immunine 
(2)	BAX326
20-40 
75	±	5
44 1-55 - Document	exposure	to	Immunine	
and	monitor	for	inhibitor	
development
-,	not	specified;	FIX,	factor	IX;	FVIII,	factor	VIII;	pdFX,	plasma-derived	factor	X;	PK,	pharmacokinetics;	rFIX,	recombinant	factor	X.
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factor	 concentrate	 products	 (Tables	 1	 and	 2).	 It	 was	 previously	
thought	 that	 switching	between	 factor	concentrates	was	associ-
ated	with	an	increased	risk	of	inhibitor	development,27 but recent 
studies	have	not	shown	consistent	results.27,28	Although	PK	data	
may	have	been	used	 in	their	statistical	analysis,	dosing	regimens	
of	each	factor	concentrate	were	not	tailored	based	on	PK.	It	was	
unclear	whether	the	dose	provided	to	the	patient	after	switching	
was	the	optimal	dosing	regimen.	Without	knowledge	of	the	dosing	
regimen	in	patients	with	hemophilia,	 it	was	also	unclear	whether	
the	overdosing	or	underdosing	of	factor	concentrate	had	an	effect	
on	inhibitor	risk.
No	inhibitor	study	that	incorporated	PK	into	its	assessment	was	
usable	to	inform	methods	for	PK-tailored	dosing.
3.4 | WAPPS‐Hemo data
As	of	September	15,	2018,	there	were	>250	centers	enrolled	world-
wide	with	>3000	patients	and	>6300	 infusions	 recorded.	 Infusion	
data	was	gathered	for	the	purposes	of	determining	the	incidence	of	
switching	between	factor	concentrates.
A	total	of	2785	patients	were	taken	from	the	WAPPS	data	plat-
form.	The	methodology	is	presented	in	Figure	1.	Of	the	2785	sub-
jects,	449	 (16%)	had	 infusions	on	≥2	concentrates,	with	 a	 total	 of	
647	switches.	A	summary	of	patient	demographics	 is	presented	 in	
Table 3.
In	terms	of	FVIII	products,	there	were	a	total	of	394	patients	and	
591	switches,	accounting	for	91%	of	total	switches	on	WAPPS-Hemo.	
FVIII	products,	classified	based	on	their	molecular	structure,	are	pre-
sented	in	Table	4.	Of	the	591	switches,	the	majority	of	the	switches	
(n	=	293)	occurred	from	second-	and	third-generation	recombinant	
full-length	products	(50%).	There	were	208	switches	(35%)	to	EHL	
products,	 73	 switches	 (12%)	 to	 B-domain–deleted	 products,	 229	
switches	(39%)	to	another	recombinant	full-length	product,	and	81	
switches	(14%)	to	plasma-derived	products.
In	terms	of	FIX	products,	there	were	a	total	of	55	patients	and	
56	switches,	accounting	for	9%	of	total	switches	on	WAPPS-Hemo.	
FIX	products,	classified	based	on	their	molecular	structure,	are	pre-
sented	 in	Table	5.	Of	 the	56	switches,	 the	majority	of	 switches	 in	
WAPPS-Hemo	occurred	when	switching	from	any	FIX	product	to	a	
recombinant	Fc-fusion	protein	FIX	product	(n	=	34),	accounting	for	
61%	of	all	FIX	switches.
4  | PHARMACOKINETIC TARGETS 
WHEN SWITCHING
While	literature	states	the	average	of	PK	parameters	(eg,	half-life)	
when	 switching	 between	 factor	 concentrates,	 the	 range	 of	 such	
PK	parameters	can	be	highly	variable.	A	study	by	Mahlangu	et	al29 
compared	the	terminal	half-life	of	the	recombinant	FVIII	Fc	fusion	
protein,	Eloctate,	with	a	standard-acting	FVIII	concentrate	(Advate)	
in	 a	phase	3	 study	 to	determine	 the	 safety,	 efficacy,	 and	PK.	On	
average,	 the	half-life	of	Eloctate	was	1.5	 times	 that	of	Advate	at	
a	dose	of	50	 IU/kg.29,30	This	provides	valuable	 information	about	
the	population,	although	it	is	clear	from	the	breadth	of	factor	con-
centrate	 brands	 being	 switched	 to	 and	 from,	 as	 identified	 in	 the	
WAPPS-Hemo	 database,	 that	 this	 type	 of	 study	 cannot	 be	 com-
pleted	for	all	scenarios.	A	study	by	Young	et	al30	demonstrated	that	
the	individual	half-life	ratios	of	FVIII	and	Eloctate	ranged	from	0.79	
to	 2.98.	 Such	 high	 half-life	 variability	within	 an	 individual	 across	
FVIII	products	makes	the	application	of	 the	mean	population	dif-
ference	irrelevant	for	use	in	individual	dosing	recommendations.
Of	particular	note	was	the	lack	of	evidence	that	standard-acting	
factor	concentrates	have	shorter	half-lives	than	 long-acting	factor	
concentrates	at	the	individual	level.	In	the	study	by	Klamroth	et	al,23 
the	majority	of	patients	had	increased	half-life	when	switching	from	
F I G U R E  3  Example	of	individual	PK	
parameters	after	switching
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TA B L E  3  Demographics	from	WAPPS	patients	who	have	
switched	between	factor	concentrates
Parameter Whole cohort FVIII FIX
Subjects	(n) 449 394 55
Switches	(n) 647 591 56
Age	(y) 1-78 1-78 2-68
Body	weight	(kg) 10-150 10-150 13-117
As	of	September	2018.
FVIII,	factor	VIII;	FIX,	factor	IX;	WAPPS,	Web-Accessible	Population	
Pharmacokinetics	Service.
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octocog	alfa	to	a	recombinant	FVIII	single-chain	concentrate;	how-
ever,	this	was	not	the	case	for	4	of	27	subjects.	The	potential	risk	of	
assuming	an	 increase	 in	half-life	when	switching	 from	a	standard-
acting	 to	 a	 long-acting	 concentrate	may	 lead	 to	 increased	 risk	 of	
bleeds	due	to	underdosing.	Without	assessing	individual	PK	param-
eters,	the	current	approach	of	using	population-level	information	to	
switch	between	factor	concentrates	may	not	yield	expected	results.
It	 would	 be	 desirable	 to	 estimate	 dosing	 regimens	 across	 a	
switch	using	an	individualized	approach.	In	an	ideal	scenario,	where	
population	 PK	 tailored	 prophylaxis	was	widely	 adopted,	 patients	
planning	on	switching	to	a	different	factor	concentrate	would	have	
information	 regarding	 their	 own	 PK	 estimates	 on	 their	 current	
factor	concentrate.	In	theory,	combining	the	knowledge	of	the	in-
dividual's	PK	of	a	factor	concentrate	prior	to	the	switch	(origin	con-
centrate)	with	the	knowledge	of	the	population	PK	characteristics	
of	the	concentrate	after	the	switch	(destination	concentrate)	may	
potentially	lead	to	the	ability	to	predict	individual	PK	estimates	of	
the	destination	concentrate.	The	accuracy	and	precision	of	such	an	
approach	have	not	yet	been	studied,	and	empirical	demonstration	
of	the	feasibility	of	the	process	is	first	required.	However,	the	per-
spective	of	enabling	better	estimation	of	individual	PK	on	the	desti-
nation	concentrate	is	undoubtedly	appealing.	This	is	an	example	of	
a	research	project	that	could	be	performed	with	the	rich	WAPPS-
Hemo	database	that	contains	many	hemophilia	subjects	who	have	
switched	between	different	factor	concentrates.
5  | STUDY LIMITATIONS
The	volume	of	 literature	we	expected	 to	 find	 in	 this	 specific	 field	
was	 limited.	As	such,	we	have	not	 registered	 the	protocol	or	used	
the	Peer	Review	of	Electronic	Search	Strategies	checklist	when	con-
ducting	our	search	strategy.	We	cast	a	wide	net	with	regards	to	our	
search	terms,	but	we	are	aware	that	this	will	 limit	the	 internal	and	
external	validity	of	our	results.
6  | CONCLUSION
Hemophilia	treatment	requires	accurate	and	individualized	dosing	
regimens	to	provide	safe,	effective,	and	cost-effective	medication	
use.	Although	 studies	 looking	 at	 bioequivalence/biosimilarity	 or	
assessing	PK	between	2	factor	concentrates	have	led	to	PK	com-
parisons,	 these	 studies	 lack	 the	 information	 required	 to	 predict	
an	optimal	dosing	 regimen	 for	hemophilia	patients	 starting	on	a	
new	product.	Studies	that	have	examined	the	development	of	in-
hibitors	did	not	mention	the	use	of	PK	parameters	to	optimize	a	
dosing	regimen.	As	such,	there	exists	no	literature	on	the	role	or	
use	of	PK	in	optimizing	factor	concentrate	dosing	during	product	
switching.
Given	 these	 limitations,	 further	 research	 is	 required	 to	 uti-
lize	PK	parameters	 from	 the	origin	product	 to	predict	 the	PK	of	
the	destination	product	 in	patients	with	hemophilia.	Due	to	sim-
ilarity	 in	 PK	 parameters,	 especially	 across	 FVIII	 products,6	 dose	
regimen	predictability	may	be	feasible	using	population	PK	meth-
ods	and	Bayesian	forecasting.	For	example,	standard-acting	FVIII	
concentrates	may	be	compared	with	other	 standard-acting	FVIII	
concentrates	and,	 in	the	same	way,	with	newer	 long-acting	FVIII	
concentrates.
With	the	introduction	of	newer	and	longer-acting	concentrates,	
the	use	of	PopPK	methods	will	be	an	integral	part	in	determining	and	
predicting	accurate	dosing	regimens	for	patients.	The	use	of	PopPK	
can	change	the	current	trial-and-error	approach	into	a	safer	dosing	
regimen	 that	makes	 use	 of	 prior	 PK	 knowledge	 to	 ensure	 patient	
safety	and	mindful	resource	consumption.
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TA B L E  5  Number	of	hemophilia	patients	from	WAPPS-Hemo	switching	between	FIX	concentrates
FIX products
Switch to
TotalPlasma‐derived Recombinant
Recombinant 
glycoPEGylated
Recombinant Fc‐
fusion protein
Recombinant albumin 
fusion protein
Switch	from Plasma-derived 4 1 0 11 1 17
Recombinant 0 1 1 22 7 31
Recombinant 
glycoPEGylated
0 0 0 0 0 0
Recombinant	Fc-
fusion	protein
1 0 1 0 5 7
Recombinant albu-
min	fusion	protein
0 0 0 1 0 1
Total 5 2 2 34 13 56
FIX,	factor	IX;	WAPPS,	Web-Accessible	Population	Pharmacokinetics	Service.
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APPENDIX 
CO‐INVESTIGATOR CONTACT INFORMATION
The	following	clinicians	have	agreed	to	participate	 in	this	phase	of	
the	WAPPS-Hemo	project	 by	 signing	 a	 co-investigator	 agreement	
(as	of	August	10,	2018):
•	 Alfonso	Iorio,	McMaster	University,	Hamilton,	Ontario,	Canada
•	 Sanjay	 Ahuja,	 University	 Hospital	 Health	 Systems	 Cleveland,	
Ohio,	USA
•	 Ma	Teresa	Álvarez	Román,	Hospital	Universitario	La	Paz,	Madrid,	
Spain
•	 Ma	 E.	 Arrieta,	 Hospital	 Público	 Descentralizado	 Dr.	 Guillermo	
Rawson,	San	Juan,	Argentina
•	 Mikko	Arola,	Tampere	University	Hospital,	Tampere,	Finland
•	 Giovanni	 Barillari,	 Center	 for	 Hemorrhagic	 and	 Thrombotic	
Diseases,	University	Hospital	of	Udine,	Italy
•	 Vinod	 Balasa,	 Valley	 Children's	 Healthcare,	 Fresno,	 California,	
USA
•	 Mark	 Belletrutti,	 University	 of	 Alberta,	 Edmonton,	 Alberta,	
Canada
•	 Ruben	 Berrueco	 Moreno,	 Hospital	 de	 Sant	 Joan	 de	 Déu,	
Barcelona,	Spain
•	 Philippe	Beurrier,	Chu,	Angers,	France
•	 Cristoph	 Bidlingmaier,	 Pediatric	 Hemophilia	 Center,	 Munich,	
Germany
•	 Victor	 Blanchette,	 Sick	 Children's	 Hospital,	 Toronto,	 Ontario,	
Canada
•	 Jan	Blatny,	University	Hospital	Brno,	Brno,	Czech	Republic
•	 Santiago	 Bonanad,	 University	 &	 Polytechnic	 Hospital	 La	 Fe,	
Valencia,	Spain
•	 Kelsey	 Brose,	 Saskatchewan	 Bleeding	 Disorders	 Program,	
Saskatoon,	Saskatchewan,	Canada
•	 Deborah	Brown,	Gulf	States	Hemophilia,	Houston,	Texas,	USA
•	 Paulette	C.	Byant,	St.	Jude	Affiliate	Clinic,	NH	Hemby	Children's	
Hospital,	Charlotte,	NC,	USA
•	 Mariana	 Canaro,	 Congenital	 Coagulopathies	 Unit	 of	 Balearic	
Islands,	Spain
•	 Manuela	Carvalho,	Centro	Hospitalar	S.	João,	Oporto,	Portugal
•	 Cristina	Catarino,	Hospital	de	Santa	Maria,	Lisbon,	Portugal
•	 Meera	Chitlur,	Children's	Hospital	of	Michigan,	Detroit,	Michigan,	
USA
•	 Erin	Cockrell,	St.	Joseph's	Hospital,	Tampa,	Florida,	USA
•	 Pratima	Chowdary,	Royal	Free	Hospital,	London,	UK
•	 Marjon	 Cnossen,	 Erasmus	 MC-Sophia	 Children's	 Hospital,	
Rotterdam,	Netherlands
•	 Peter	Collins,	Arthur	Bloom	Centre,	Cardiff,	UK
•	 Michial	 Coppens,	 Academic	 Medical	 Center	 Amsterdam,	
Amsterdam,	The	Netherlands
•	 Stacy	Croteau,	Dana-Farber/Boston	Children's	Hospital,	Boston,	
USA
•	 Dorina	Cultrera,	Policlinico-Vittorio	Emanuele,	Catania,	Italy
•	 Raimundo	 de	 Cristofaro,	 Università	 Cattolica	 S.	 Cuore,	 Rome,	
Italy
•	 Emmauelle	de	Raucourt,	Clinic	des	Anticoagulants	(CAC),	Clichy,	
France
•	 Dominique	Desprez,	Hospital	de	HautePierre,	CHU	de	Strasbourg,	
France
•	 Amy	Dunn,	Nationwide	Children's	Hospital,	Columbus,	Ohio,	USA
•	 Magda	El-Ekiabi,	Shabrawishi	Hospital	Blood	Bank,	Egypt
•	 Barbara	 Faganel	 Kotnik,	 Haemophilia	 Comprehensive	 Care	
Center,	Slovenia
•	 Kathleen	Fischer,	University	Medical	Center	(UMC)	Utrecht,	The	
Netherlands
•	 Brigit	Frotscher,	CHU	Nancy,	France
•	 Susana	 Garbiero,	 Centro	 Asistencial	 Regional	 de	 Hemoterapia	
(CARDHE),	Bahia	Blanca,	Argentina
•	 Raquel	Garrido	Ruiz,	Hospital	Universitario	de	Puerto	Real,	Cádiz,	
Spain
•	 Joan	Gill,	Blood	Research	Institute,	Milwaukee,	Wisconsin,	USA
•	 Carmen	Gomez	del	Castillo,	Complexo	Hospitalario	Universitario,	
Coruña,	Spain
•	 Saskia	 Gottstein,	 Vivantes	 Clinic	 in	 Friedrichshain,	 Berlin,	
Germany
•	 Giuseppe	Lassandro	and	Paola	Giordano,	U.O.	Pediatria	Generale	
e	Specialistica	B.	Trambusti,	Bari,	Italy
•	 Daniel	Hart,	Royal	London	Hospital,	London,	UK
•	 Inga	Hegemann,	Zurich	University	Hospital,	Zurich,	Switzerland
•	 Cedric	Hermans,	St-Luc	University	Hospital,	Brussels,	Belgium
•	 Baolai	Hua,	Peking	Union	Medical	College	Hospital,	Beijing,	
China
•	 Nina	 Hwang,	 Center	 for	 Inherited	 Blood	 Disorders	 (CIBD),	
Orange,	California,	USA
•	 Shannon	Jackson,	St.	Paul's	Hospital,	Vancouver,	British	Columbia,	
Canada
•	 Paula	 James,	 SE	Ontario	 Regional	 Inherited	 Bleeding	Disorders	
Program,	Kingston,	Canada
•	 Olga	Katsarou,	Laiko	General	Hospital,	Athens,	Greece
•	 Kaan	Kavakli,	Ege	University	Hospital,	Izmir,	Turkey
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•	 Christine	Kempton,	AFLAC	Cancer	Center	 and	Blood	Disorders	
Services,	Atlanta,	Georgia,	USA
•	 Karim	Kentouche,	Universitätsklinikum	Jena,	Jena,	Germany
•	 Osman	 Khan,	 Oklahoma	 Center	 for	 Bleeding	 and	 Clotting	
Disorders,	Oklahoma	City,	Oklahoma,	USA
•	 Rainer	Kobelt,	University	Children's	Hospital,	Berne,	Switzerland
•	 Rebecca	 Kruse-Jarres,	 Harborview	 Medical	 Center,	 Seattle,	
Washington,	USA
•	 Edward	Laane,	North	Estonia	Medical	Center,	Tallinn,	Estonia
•	 Eric	 Larson,	 Maine	 Hemophilia	 and	 Thrombosis	 Centre,	
Scarborough,	Maine,	USA
•	 Riitta	 Lassila,	 Coagulation	 Disorders	 in	 Helsinki	 University	
Hospital,	Finland
•	 Adrienne	 Lee	 and	 Man-Chiu	 Poon,	 Foothills	 Medical	 Centre,	
Calgary,	Alberta,	Canada
•	 Jennifer	Lissick,	Children's	of	Minnesota,	Minneapolis,	Minnesota,	
USA
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